An HIV-1 Mini Vaccine Induced Long-lived Cellular and Humoral Immune Responses

Memory formation is the most important aspect of a vaccine which can guarantee long-lasting immunity and protection. The main aim of the present study was to evaluate the memory immune responses after immunization with a mini vaccine. Mice were immunized with human immunodeficiency virus-1 P24-Nef fusion peptide and then cellular and humoral immune responses were evaluated. In order to determine long-lived memory, immune responses were monitored for 20 weeks after final immunization. The results showed that the candidate vaccine induced proliferation and cytotoxic T lymphocyte responses and shifted cytokine patterns to T helper-1 profile. Evaluation of humoral immune responses also showed an increase in total peptide specific-IgG titer and a shift to IgG2a humoral response. Monitoring of immune responses at weeks 4, 12 and 20 after last immunization showed that immunologic parameters have been sustained for 20 weeks. Our findings support the notion that long-lived memory responses were achieved using a mini vaccine immunization.

[1]  Z. Hassan,et al.  ELISPOT analysis of a new CTL based DNA vaccine for HIV-1 using GM-CSF in DNA prime/peptide boost strategy: GM-CSF induced long-lived memory responses. , 2011, Immunology letters.

[2]  Z. Hassan,et al.  Immunogenicity of a new HIV-1 DNA construct in a BALB/c mouse model. , 2009, Iranian journal of immunology : IJI.

[3]  Hildegund C. J. Ertl,et al.  Obstacles to the successful development of an efficacious T cell‐inducing HIV‐1 vaccine , 2009, Journal of leukocyte biology.

[4]  A. Karami,et al.  Effect of immunological adjuvants: GM-CSF (granulocyte-monocyte colony stimulating factor) and IL-23 (interleukin-23) on immune responses generated against hepatitis C virus core DNA vaccine. , 2009, Cytokine.

[5]  Abbas Jamali,et al.  A novel adjuvant, the general opioid antagonist naloxone, elicits a robust cellular immune response for a DNA vaccine. , 2009, International immunology.

[6]  B. Haynes,et al.  Safety and immunogenicity of a CTL multiepitope peptide vaccine for HIV with or without GM-CSF in a phase I trial. , 2009, Vaccine.

[7]  D. Masopust.  Developing an HIV cytotoxic T‐lymphocyte vaccine: issues of CD8 T‐cell quantity, quality and location , 2009, Journal of internal medicine.

[8]  B. Korber,et al.  Expanded Breadth of the T-Cell Response to Mosaic Human Immunodeficiency Virus Type 1 Envelope DNA Vaccination , 2008, Journal of Virology.

[9]  M. Roederer,et al.  T-cell quality in memory and protection: implications for vaccine design , 2008, Nature Reviews Immunology.

[10]  S. Self,et al.  Towards prediction of degenerate CTL epitope recognition , 2008, Human vaccines.

[11]  D. Ficheux,et al.  Induction of Human Immunodeficiency Virus (HIV-1) Envelope Specific Cell-Mediated Immunity by a Non-Homologous Synthetic Peptide , 2007, PloS one.

[12]  Abbas Jamali,et al.  Naloxone, an opioid receptor antagonist, enhances induction of protective immunity against HSV-1 infection in BALB/c mice. , 2007, Microbial pathogenesis.

[13]  T. Delair,et al.  Formulation of HIV-1 Tat and p24 antigens by PLA nanoparticles or MF59 impacts the breadth, but not the magnitude, of serum and faecal antibody responses in rabbits. , 2007, Vaccine.

[14]  P. Rácz,et al.  Multiprotein genetic vaccine in the SIV‐Macaca animal model: a promising approach to generate sterilizing immunity to HIV infection , 2007, Journal of medical primatology.

[15]  G. Pantaleo,et al.  Generation and immunogenicity of novel HIV/AIDS vaccine candidates targeting HIV-1 Env/Gag-Pol-Nef antigens of clade C. , 2007, Vaccine.

[16]  J. Mullins,et al.  Comprehensive epitope analysis of cross-clade Gag-specific T-cell responses in individuals with early HIV-1 infection in the US epidemic. , 2007, Vaccine.

[17]  A. McMichael,et al.  Induction of long‐lasting multi‐specific CD8+ T cells by a four‐component DNA‐MVA/HIVA‐RENTA candidate HIV‐1 vaccine in rhesus macaques , 2006, European journal of immunology.

[18]  P. Earl,et al.  Studies on GM-CSF DNA as an adjuvant for neutralizing Ab elicited by a DNA/MVA immunodeficiency virus vaccine. , 2006, Virology.

[19]  K. Rosenthal,et al.  Vaccines: All Things Considered , 2006, Clinical and Vaccine Immunology.

[20]  Scott A. Brown,et al.  Long lived multi-isotype anti-HIV antibody responses following a prime-double boost immunization strategy. , 2005, Vaccine.

[21]  E. Rosenberg,et al.  Comprehensive Analysis of Human Immunodeficiency Virus Type 1-Specific CD4 Responses Reveals Marked Immunodominance of gag and nef and the Presence of Broadly Recognized Peptides , 2004, Journal of Virology.

[22]  J. Shiver,et al.  Development of HIV-1 Nef vaccine components: immunogenicity study of Nef mutants lacking myristoylation and dileucine motif in mice. , 2002, Vaccine.

[23]  Andreas Radbruch,et al.  Humoral immunity and long-lived plasma cells. , 2002, Current opinion in immunology.

[24]  Derek T. O'Hagan,et al.  Recent Advances in Vaccine Adjuvants , 2002, Pharmaceutical Research.

[25]  M. L. Mackichan,et al.  Recent developments in adjuvants for vaccines against infectious diseases. , 2001, Biomolecular engineering.

[26]  T. Kepler,et al.  Human immunodeficiency virus type 1-specific cytotoxic T lymphocyte activity is inversely correlated with HIV type 1 viral load in HIV type 1-infected long-term survivors. , 1999, AIDS research and human retroviruses.

[27]  G. Pialoux,et al.  [HIV vaccines]. , 2005, Presse medicale.

[28]  W. Kastenmuller,et al.  Infectious Agents and Cancer Immunization of Mice with the Nef Gene from Human Immunodeficiency Virus Type 1: Study of Immunological Memory and Long-term Toxicology , 2022 .